No Data
No Data
CSPC Pharmaceutical's Nine-Month Profit Declines 16%
[Hong Kong Stock Connect] cspc pharma (01093) reported a 15.94% year-on-year decrease in net income for the first three quarters.
Jinwu Financial News | cspc pharma (01093) announced its quarterly performance for the nine months ending September 30, 2024. During the period, the profit attributable to shareholders was 3.778 billion yuan (RMB, the same below), a decrease of 15.94% year-on-year; basic earnings per share were 32.03 cents. During the period, the group's income was 22.686 billion yuan, a decrease of 4.94% year-on-year. The decline in income was mainly influenced by the drop in business revenue from finished medicines. Specifically, finished medicine revenue was 18.67 billion yuan, a decrease of 3.5% year-on-year; revenue from raw materials was 2.726 billion yuan, a decrease of 5.2%; revenue from functional foods and other was 1.
CSPC Pharmaceutical 9-Mos Net CNY3.78B Vs. Net CNY4.49B >1093.HK
In the first half of the year, cspc pharma's net profit was 3.778 billion yuan, with over 60 key drugs in research having entered clinical or申报 stages.
CSPC Pharma (01093.HK) announced on November 15th that, for the nine months ended September 30, 2024, the revenue was RMB 22.686 billion, a 4.9% decrease from the same period last year. This was mainly due to the decline in revenue from the pharmaceutical business, with the attributable basic earnings per shareholder falling by 15.2% to RMB 3.999 billion from the same period last year, and the attributable earnings per shareholder dropping by 15.9% to RMB 3.778 billion. During the reporting period, revenue from the pharmaceutical business decreased by 3.5% to RMB 18.67 billion; revenue from raw material products business decreased by 5.2% to RMB 27 billion.
Express News | CSPC Pharmaceutical Group 9M Revenue RMB 22,686 Million
CSPC PHARMA: QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Willis88 : Junk stocks